FMO2

FMO2 is a multifunctional ER-anchored flavoprotein that serves both as an NADPH-dependent monooxygenase catalyzing N- and S-oxygenation of xenobiotics and as a non-enzymatic scaffold regulating lipid metabolism, calcium signaling, DNA repair, and immune signaling. The full-length enzyme (encoded by the FMO2*1 allele) requires its C-terminal 64 residues for catalytic activity, as the predominant human allele (Q472X) produces a truncated, catalytically inactive protein that nonetheless localizes to ER membranes (PMID:9804831, PMID:11302936). Independent of its enzymatic function, FMO2 competitively displaces SCAP from SREBP1 to block ER-to-Golgi translocation and suppress hepatic lipogenesis (PMID:37874228), maintains ER–mitochondria contacts via an IP3R2–Grp75–VDAC1 complex to regulate mitochondrial Ca²⁺ transfer in cardiomyocytes (PMID:40489543), stabilizes chromatin-bound XLF to promote DNA double-strand break repair (PMID:40752568), and sequesters GYS1 from PJA1-mediated ubiquitination to activate NF-κB/CCL19 signaling in cancer-associated fibroblasts (PMID:40316306). FMO2 expression is transcriptionally induced by the AMPK–KLF4 axis and post-transcriptionally suppressed by the RNA-binding proteins CELF1 and CELF4, which promote FMO2 mRNA decay via 3′UTR binding (PMID:39491669, PMID:40021568, PMID:40610856).

1. 1994 High

   Establishing FMO2 as a catalytically distinct monooxygenase: recombinant rabbit FMO2 showed unique sulfoxidation kinetics and stereoselectivity compared with other FMO family members, defining it as a functionally autonomous enzyme rather than a redundant paralog.

   Evidence E. coli–expressed rabbit FMO2 with kinetic (Km, Vmax) and enantiomeric excess measurements of sulfoxidation products

   PMID:8203899

   Open questions at the time

   • Human FMO2 substrate spectrum not yet characterized
   • No structural basis for stereoselectivity
2. 1998 High

   Explaining why most humans lack pulmonary FMO2 activity: identification of the Q472X nonsense mutation in the major human allele showed the C-terminal region is indispensable for catalysis, a conclusion confirmed by expression of the equivalent truncation in macaque FMO2.

   Evidence cDNA cloning/sequencing, heterologous expression with catalytic assays, and primate comparative genomics [1998]; baculovirus-expressed macaque full-length vs. truncated FMO2 [2001]; genotype–protein–activity correlation in human lung microsomes [2000]

   PMID:11042094 PMID:11302936 PMID:9804831

   Open questions at the time

   • Structural mechanism by which C-terminal truncation abolishes catalysis unknown
   • Frequency of functional FMO2*1 in non-African populations not established
3. 2009 High

   Defining catalytic residues and cofactor interactions: characterization of S195L and N413K variants revealed that S195 is critical for NADPH binding affinity, refining the mechanistic model of FMO2 cofactor utilization.

   Evidence Baculovirus-expressed SNP variants with full kinetic profiling (Km for NADPH, Vmax, kcat) and thermal/pH/detergent stability assays

   PMID:19420133

   Open questions at the time

   • No crystal structure of FMO2 to confirm predicted cofactor contacts
   • Impact of these variants in vivo unknown
4. 2023 High

   Revealing an enzyme-independent scaffolding role in lipid metabolism: FMO2 directly binds SREBP1 (aa 217–296) and competitively displaces SCAP, blocking SREBP1 ER-to-Golgi translocation and suppressing de novo lipogenesis — a function independent of its monooxygenase activity.

   Evidence Co-IP with domain mapping, competitive binding assay, hepatocyte-specific KO/OE mouse models with NAFLD phenotyping, RNA-seq

   PMID:37874228

   Open questions at the time

   • Whether the truncated Q472X protein retains SREBP1-binding capacity is untested
   • Regulation of FMO2 expression in hepatocytes not defined
5. 2024 Medium

   Identifying the upstream transcriptional axis controlling cardiac FMO2: exercise-induced AMPK activation drives KLF4-mediated FMO2 transcription, and AAV9-mediated FMO2 knockdown abolished exercise-conferred cardiac protection.

   Evidence AAV9 FMO2 knockdown in vivo, AMPK activation experiments, KLF4 transcription factor identification, sympathetic overactivation mouse model

   PMID:39491669

   Open questions at the time

   • Direct KLF4 binding to FMO2 promoter not shown by ChIP
   • Whether AMPK–KLF4 axis operates in non-cardiac tissues unknown
6. 2025 High

   Establishing FMO2 as a MAM-resident scaffold for ER–mitochondria Ca²⁺ signaling: FMO2 localizes to MAMs and forms a complex with IP3R2–Grp75–VDAC1, maintaining mitochondrial Ca²⁺ transfer; cardiac-specific KO exacerbated and OE prevented pathological hypertrophy.

   Evidence MAM-targeted proteomics, Co-IP of complex components, cardiac-specific KO and AAV9-OE mouse models, Ca²⁺ imaging in neonatal rat cardiomyocytes

   PMID:40489543

   Open questions at the time

   • Stoichiometry and direct vs. bridged interaction with each complex member unresolved
   • Whether MAM function is enzymatic or purely scaffolding not dissected
7. 2025 Medium

   Linking FMO2 to DNA repair: FMO2 stabilizes chromatin-bound XLF to facilitate NHEJ-mediated DNA double-strand break repair, protecting cardiomyocytes from doxorubicin-induced damage.

   Evidence FMO2 KO and cardiomyocyte-specific OE mouse models, chromatin analysis, XLF stability assays, xenograft tumor model

   PMID:40752568

   Open questions at the time

   • Mechanism of XLF stabilization (direct binding vs. indirect) not defined
   • Single-lab finding awaiting independent replication
8. 2025 Medium

   Revealing a non-enzymatic role in immune microenvironment remodeling: in cancer-associated fibroblasts, FMO2 sequesters GYS1 from PJA1-mediated ubiquitination, enabling GYS1 accumulation that activates NF-κB/p65-driven CCL19 transcription and tertiary lymphoid structure formation.

   Evidence Co-IP (FMO2–GYS1–PJA1), ubiquitination assay, NF-κB reporter, orthotopic HCC mouse model, scRNA-seq, spatial transcriptomics, CyTOF

   PMID:40316306

   Open questions at the time

   • FMO2–GYS1 binding interface not mapped
   • Relevance outside hepatocellular carcinoma unclear
   • Single-lab finding
9. 2025 Medium

   Defining post-transcriptional regulation of FMO2: CELF1 and CELF4 independently bind FMO2 mRNA (3′UTR GU-rich elements) and promote its decay, establishing mRNA stability as a key regulatory node for FMO2 levels in cardiac fibroblasts.

   Evidence RIP, RNA pull-down with biotinylated elements, luciferase 3′UTR reporter, actinomycin D decay assay, CELF KO/KD mouse models with cardiac phenotyping

   PMID:40021568 PMID:40610856

   Open questions at the time

   • Whether CELF1 and CELF4 target overlapping or distinct sites on FMO2 3′UTR not compared
   • Impact of post-transcriptional regulation on non-cardiac FMO2 functions untested

• It remains unknown how FMO2's multiple non-enzymatic scaffold functions (SREBP1 binding, MAM tethering, XLF stabilization, GYS1 sequestration) are coordinated or mutually exclusive across cell types, and whether the prevalent Q472X truncated human protein retains any of these scaffold activities.
• No structure of human FMO2 to map overlapping vs. separate interaction surfaces
• Truncated Q472X protein has never been tested for non-enzymatic functions
• No systems-level study integrating enzymatic and scaffolding roles across tissues